Net earnings per share (EPS TTM): VYNE Therapeutics Inc (VYNE)

Public company logo of vynetherapeutics.com (VYNE)

VYNE Therapeutics (VYNE) is implementing software robots for clinical data analysis and developing highly scalable inhibitors for autoimmune skin pathologies. This daily price chart from GURU.Markets showing the current rolling annual EPS indicates that -26.89 represents the latest level. However, VYNE Therapeutics (VYNE) faces intense pressure from pharma behemoths engaged in an aggressive battle for patient attention.

VYNE vynetherapeutics.com Earnings per share for the last 12 months (07/04/2022 - 07/28/2026)

Analytical breakdowns and data insights for company VYNE Therapeutics (VYNE)

- current quotes and average value forecast:
- company stock exchange capitalization indicators:
Fundamental valuation:vynetherapeutics.com (VYNE)
Flagship merchandise of VYNE Therapeutics Inc

This metric is calculated by dividing the total annual net income by the total number of outstanding shares. It measures real capital efficiency, signaling business stagnation when values remain excessively stable. For VYNE Therapeutics (VYNE), this balance is critical, as the development of unique molecule delivery systems requires massive investments. GURU.Markets analysts recommend using the rolling trailing twelve-month earnings per share to identify hidden financial risks. The price action on this chart determines the viability of the company's innovative model.